Breast Cancer Clinical Trial
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Summary
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated stop-smoking program with the usual care for patients receiving treatment for early-stage cancer.
Full Description
OBJECTIVES:
Compare the efficacy of brief physician-initiated smoking cessation strategies vs usual care in patients with early stage cancer who are undergoing treatment in clinical oncology settings.
Compare the sociodemographic, smoking history, and health status correlates of smoking cessation in patients treated with these regimens.
Determine the feasibility of conducting a cancer prevention and control study in a cooperative group setting by monitoring adherence to the smoking-cessation strategies.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive usual care (no special intervention).
Arm II: Patients receive smoking-cessation therapy based on the 4-step intervention plan in the "Manual for Physicians" published by the National Cancer Institute. The smoking cessation coordinator and physician provide self-quitting advice and support to the patient via counseling, self-help materials, and referral to a smoking cessation counselor at the Cancer Information Service (CIS). Patients receive nicotine replacement, if indicated. Patients who express an interest in more intensive treatment are referred to local American Cancer Society or American Lung Association clinics and/or advised to call the CIS for additional local program referrals.
All patients are followed at 6 and 12 months. Patients who report that they are still smoking and interested in help to quit smoking at the 12-month follow-up interview are encouraged to return to their physicians and contact the CIS for additional help quitting or for a referral to more intensive or specialized treatments in their area.
PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
One of the following diagnoses:
Stage I or II bladder, colorectal, head and neck, lung, or other cancer
Stage I-III testicular cancer
Stage I-IV breast cancer, prostate cancer, or lymphoma
Must have smoked 1 or more cigarettes within the past month or define self as a smoker
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age:
19 and over
Sex:
Not specified
Menopausal status:
Not specified
Performance status:
ECOG 0-1
Life expectancy:
Not specified
Hematopoietic:
Not specified
Hepatic:
Not specified
Renal:
Not specified
Cardiovascular:
No history of recent heart attack
Other:
Not pregnant
No other imminent medical needs requiring referral to a more intensive smoking cessation regimen
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
Not specified
Endocrine therapy:
Not specified
Radiotherapy:
Not specified
Surgery:
Not specified
Other:
No prior participation in the pilot phase study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19111, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.